Optimization of a small-molecule Lipid II binder

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• Lipid II is a crucial precursor in bacterial cell wall biosynthesis and a promising antibiotic target.
• The previously identified compound 6jc48-1 interacts with multiple components of Lipid II, including the MurNAc moiety, pyrophosphate, and isoprenyl tail.

Purpose of the Study:

• To investigate the structure-activity relationship of 6jc48-1 derivatives for improved antibacterial properties.
• To understand how modifications affect compound interaction with Lipid II and bacterial killing.

Main Methods:

• De novo chemical synthesis of 6jc48-1 derivatives.
• Evaluation of antibacterial activity against relevant bacterial strains.
• Assessment of compound binding to Lipid II and cytotoxicity.

Main Results:

• Bacterial killing efficacy is enhanced by bi-phenyl stacking interactions with peptidoglycan units.
• Replacing bromide with fluoride in the compound structure led to activity against Staphylococcus aureus.
• This fluoride substitution did not alter Lipid II binding affinity or cytotoxicity.
• Extended interactions with the Lipid II isoprenyl tail negatively impacted antibacterial activity.

Conclusions:

• The pyrylium boron tetrafluoride scaffold can be optimized for potent antibacterial activity through targeted structural modifications.
• Fluorinated derivatives represent a promising avenue for developing new antibiotics against Gram-positive bacteria like S. aureus.
• Fine-tuning the interaction with Lipid II is key to maximizing efficacy and minimizing off-target effects.